The overall picture emerging from this survey, conducted two years apart from the previous one, suggests a greater awareness of endocrinologists about the potential of treating patients with obesity with GLP1 receptor agonists, with less worries about side effects and patient resistance. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.